2C-P

From Wikipedia, the free encyclopedia
Jump to: navigation, search
2C-P
2C-P2DACS.svg
2C-P-3d-sticks.png
2C-P animation.gif
Names
IUPAC name
2-(2,5-Dimethoxy-4-propylphenyl)ethanamine
Identifiers
207740-22-5 N
ChEMBL ChEMBL339136 YesY
ChemSpider 21106226 YesY
Jmol-3D images Image
PubChem 44350080
Properties
C13H21NO2
Molar mass 223.3126 g/mol
Melting point 207 to 209 °C (405 to 408 °F; 480 to 482 K) (hydrochloride)
7-9 mg/ml (20 °C)
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

2C-P is a relatively potent and long acting psychedelic phenethylamine and 2C compound first synthesized by Alexander Shulgin.

Chemistry[edit]

2C-P is 2,5-dimethoxy-4-(n)-propylphenethylamine. The full name of the chemical is 2-(2,5-dimethoxy-4-propylphenyl)ethanamine. The hydrochloride salt is the most common form, normally found as a white powder,[1] or white crystals.[2] Shulgin's 2C-P crude freebase (soluble in chloroform), after "removal of the solvent under vacuum," was an off-white colored oil which he distilled at 100–110 °C at 0.3 mm/Hg (turning it "water white" in color), and it "spontaneously crystallized" upon cooling.

Effects[edit]

2C-P produces intense hallucinogenic, psychedelic, and entheogenic effects including open eye visualizations and closed-eye visualizations.[2] It can have a very slow onset if ingested, and peak effects reportedly do not occur for 3 to 5 hours.[2] The peak last for five to ten hours, with the overall experience lasting up to 20 hours. Some users reports that their 2C-P experiences have lasted anywhere between 10 to 24 hours, or even longer (up to 26 hours with a re-dose or supplemental dosages being taken after the initial dose[3]) with higher doses between 16-20 milligrams as some users reported.[4]

Dosage[edit]

In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed 2C-P's dosage range as 6–10 mg and wrote that while most reports with dosages between 6 and 12 mg were favorable, "there was one report of an experience in which a single dosage of 16 mg was clearly an overdose, with the entire experiment labeled a physical disaster, not to be repeated."[2] He cautioned readers regarding dosing with 2C-P by commenting that "a consistent observation is that there may not be too much latitude in dosage between that which would be modest, or adequate, and that which would be excessive. The need for individual titration would be most important with this compound."[2] 2C-P is one of the most potent compounds in the 2C family of psychedelics, rivaled only by 2C-TFM.

Overdoses and deaths[edit]

"Overdoses" (merely taking an amount that caused too many unwanted effects) without death have been reported with as little as 12 mg orally.[3] Unknown (or unreported) dosages taken by teenagers at a Connecticut, USA concert in September 2013 caused seven people (presumed teenagers) to require emergency medical help including CPR and defibrillation to resuscitate some of them, with all seven being taken to a hospital and four of those being hospitalized until at least the next day[5] Confusingly, it was reported that none of the overdose victims died[6] while CNN's "OutFront" blog claimed the police called it a "mass casualty event"[7] blaming the problems on 2C-P and drugs apparently being sold as "Molly."

In popular culture[edit]

In the first episode of the CBS fictional TV drama series Battle Creek, a local police detective in Battle Creek, Michigan is tasked with solving a double murder where an assisting FBI agent claims (according to his lab technicians) the victims were operating a clandestine laboratory manufacturing 2C-P.

Legal status[edit]

2C-P is not scheduled by the United Nations' Convention on Psychotropic Substances.

Denmark[edit]

In Denmark (EU), 2C-P has been added to the list of Schedule B controlled substances.[8]

USA[edit]

2C-P was specifically placed into Schedule I (with the DEA Drug Code of 7524) making it illegal to possess, distribute and/or manufacture without a license in the United States by an act of the US Congress on July 9, 2012 when US President Obama signed the Synthetic Drug Abuse Prevention Act of 2012 (SDAPA).[9] The law came into effect on January 4, 2013.[10]

References[edit]

External links[edit]